Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition

Journal of Controlled Release

Volumn 170, Issue 2, 2013, Pages 183-190

  Bonnet, Marie Elise ^a   Gossart, Jean Baptiste ^a   Benoit, Elodie ^a   Messmer, Mélanie ^b   Zounib, Omar ^a   Moreau, Valérie ^a   Behr, Jean Paul ^a   Lenne Samuel, Nathalie ^a   Kedinger, Valérie ^a   Meulle, Aline ^a   Erbacher, Patrick ^a   Bolcato Bellemin, Anne Laure ^a  

^a Polyplus transfection SA   (France)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Cancer; Cell cycle; Delivery; Metastasis; Sticky siRNA

Indexed keywords

BIOLOGICAL ORGANS; CELL PROLIFERATION; CHEMOTHERAPY; CYTOLOGY; DISEASES; NUCLEIC ACIDS; PATHOLOGY; PLATINUM COMPOUNDS; RNA; TUMORS;

CANCER; CELL CYCLE; DELIVERY; METASTASIS; STICKY SIRNA;

CELLS;

CYCLIN B1; POLYETHYLENEIMINE; SMALL INTERFERING RNA; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, MOUSE; CCNB1 PROTEIN, MOUSE; CISPLATIN; INHIBITOR OF APOPTOSIS PROTEIN; REPRESSOR PROTEIN;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; LUNG METASTASIS; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICOLOGY; ADENOCARCINOMA; ANIMAL; CHEMISTRY; FEMALE; GENETICS; LD 50; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN B1; FEMALE; INHIBITOR OF APOPTOSIS PROTEINS; LETHAL DOSE 50; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; POLYETHYLENEIMINE; REPRESSOR PROTEINS; RNA, SMALL INTERFERING;

EID: 84879490865     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.05.015     Document Type: Article

References (50)

1. S.M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, T. Tuschl, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature 411 (2001) 494-498. (Pubitemid 32494397)
2. S.M. Elbashir, J. Harborth, K. Weber, T. Tuschl, Analysis of gene function in somatic mammalian cells using small interfering RNAs, Methods 26 (2002) 199-213. (Pubitemid 34969582)
3. M. Wang, A.L. Gartel, The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA, Oncotarget 2 (2011) 1218-1226.
4. Q. Ge, L. Filip, A. Bai, T. Nguyen, H.N. Eisen, J. Chen, Inhibition of influenza virus production in virus-infected mice by RNA interference, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8676-8681. (Pubitemid 38745830)
5. T. Segura, H. Schmokel, J.A. Hubbell, RNA interference targeting hypoxia inducible factor 1alpha reduces post-operative adhesions in rats, J. Surg. Res. 141 (2007) 162-170. (Pubitemid 47042044)
6. B. Urban-Klein, S. Werth, S. Abuharbeid, F. Czubayko, A. Aigner, RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo, Gene Ther. 12 (2005) 461-466. (Pubitemid 40394299)
7. A.L. Bolcato-Bellemin, M.E. Bonnet, G. Creusat, P. Erbacher, J.P. Behr, Sticky overhangs enhance siRNA-mediated gene silencing, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 16050-16055. (Pubitemid 350099361)
8. M. Wilda, A.V. Perez, J. Bruch, W. Woessmann, M. Metzler, U. Fuchs, A. Borkhardt, Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5), Genes Chromosomes Cancer 43 (2005) 424-426. (Pubitemid 40946477)
9. C.A. Schmitt, Senescence, apoptosis and therapy - cutting the lifelines of cancer, Nat. Rev. Cancer 3 (2003) 286-295. (Pubitemid 37328864)
10. D.C. Altieri, Survivin, versatile modulation of cell division and apoptosis in cancer, Oncogene 22 (2003) 8581-8589. (Pubitemid 38019195)
11. L. O'Driscoll, R. Linehan, M. Clynes, Survivin: role in normal cells and in pathological conditions, Curr. Cancer Drug Targets 3 (2003) 131-152. (Pubitemid 36389551)
12. S. Fukuda, L.M. Pelus, Survivin, a cancer target with an emerging role in normal adult tissues, Mol. Cancer Ther. 5 (2006) 1087-1098. (Pubitemid 43881300)
13. R.K. Kanwar, C.H. Cheung, J.Y. Chang, J.R. Kanwar, Recent advances in anti-survivin treatments for cancer, Curr. Med. Chem. 17 (2010) 1509-1515.
14. B.M. Ryan, N. O'Donovan, M.J. Duffy, Survivin: a new target for anti-cancer therapy, Cancer Treat. Rev. 35 (2009) 553-562.
15. J. Yuan, R. Yan, A. Kramer, F. Eckerdt, M. Roller, M. Kaufmann, K. Strebhardt, Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells, Oncogene 23 (2004) 5843-5852. (Pubitemid 39093030)
16. P. Jin, S. Hardy, D.O. Morgan, Nuclear localization of cyclin B1 controls mitotic entry after DNA damage, J. Cell Biol. 141 (1998) 875-885. (Pubitemid 28243956)
17. X.Y. Yin, L. Grove, N.S. Datta, K. Katula, M.W. Long, E.V. Prochownik, Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression, Cancer Res. 61 (2001) 6487-6493. (Pubitemid 32785287)
18. C. Santana, E. Ortega, A. Garcia-Carranca, Oncogenic H-ras induces cyclin B1 expression in a p53-independent manner, Mutat. Res. 508 (2002) 49-58.
19. N. Sarafan-Vasseur, A. Lamy, J. Bourguignon, F. Le Pessot, P. Hieter, R. Sesboue, C. Bastard, T. Frebourg, J.M. Flaman, Overexpression of B-type cyclins alters chromosomal segregation, Oncogene 21 (2002) 2051-2057. (Pubitemid 34270893)
20. J.C. Soria, S.J. Jang, F.R. Khuri, K. Hassan, D. Liu, W.K. Hong, L. Mao, Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication, Cancer Res. 60 (2000) 4000-4004. (Pubitemid 30636572)
21. K.A. Hassan, K.K. Ang, A.K. El-Naggar, M.D. Story, J.I. Lee, D. Liu, W.K. Hong, L. Mao, Cyclin B1 overexpression and resistance to radiotherapy in head and neck squa-mous cell carcinoma, Cancer Res. 62 (2002) 6414-6417. (Pubitemid 35364097)
22. D. Korenaga, F. Takesue, M. Yasuda, M. Honda, T. Nozoe, S. Inutsuka, The relationship between cyclin B1 overexpression and lymph node metastasis in human co-lorectal cancer, Surgery 131 (2002) S114-S120. (Pubitemid 34118626)
23. S. Takeno, T. Noguchi, R. Kikuchi, Y. Uchida, S. Yokoyama, W. Muller, Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma, Cancer 94 (2002) 2874-2881. (Pubitemid 34547686)
24. M. Yasuda, F. Takesue, S. Inutsuka, M. Honda, T. Nozoe, D. Korenaga, Overexpression of cyclin B1 in gastric cancer and its clinicopathological significance: an immunohistological study, J. Cancer Res. Clin. Oncol. 128 (2002) 412-416. (Pubitemid 35007551)
25. T. Yoshida, S. Tanaka, A. Mogi, Y. Shitara, H. Kuwano, The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer, Ann. Oncol. 15 (2004) 252-256. (Pubitemid 38262624)
26. W.A. Cooper, M.R. Kohonen-Corish, B. McCaughan, C. Kennedy, R.L. Sutherland, CS. Lee, Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer, Histopathology 55 (2009) 28-36.
27. M. Ozeki, D. Tamae, D.X. Hou, T. Wang, T. Lebon, D.R. Spitz, J.J. Li, Response of cyclin B1 to ionizing radiation: regulation by NF-kappaB and mitochondrial antioxidant enzyme MnSOD, Anticancer Res. 24 (2004) 2657-2663. (Pubitemid 39407140)
28. Z. Li, L. Xia, L.M. Lee, A. Khaletskiy, J. Wang, J.Y. Wong, J.J. Li, Effector genes altered in MCF-7 human breast cancer cells after exposure to fractionated ionizing radiation, Radiat. Res. 155 (2001) 543-553. (Pubitemid 32260252)
29. F. Cavallo, E. Di Carlo, M. Butera, R. Verrua, M.P. Colombo, P. Musiani, G. Forni, Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12, Cancer Res. 59 (1999) 414-421. (Pubitemid 29048877)
30. M. Giovarelli, P. Musiani, A. Modesti, P. Dellabona, G. Casorati, A. Allione, M. Consalvo, F. Cavallo, F. Di Pierro, C. De Giovanni, T. Musso, G. Forni, Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory, J. Immunol. 155 (1995) 3112-3123.
31. N. Murray, A.T. Turrisi III, A review of first-line treatment for small-cell lung cancer, J. Thorac. Oncol. 1 (2006) 270-278. (Pubitemid 47181446)
32. LA Porter, G. Singh, J.M. Lee, Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis, Blood 95 (2000) 2645-2650. (Pubitemid 30210545)
33. L.A. Porter, I.H. Cukier, J.M. Lee, Nuclear localization of cyclin B1 regulates DNA damage-induced apoptosis, Blood 101 (2003) 1928-1933. (Pubitemid 36237595)
34. A. Dutta, R. Chandra, L.M. Leiter, S. Lester, Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer, Proc. Natl. Acad. Sci. U. S. A 92 (1995) 5386-5390.
35. M.C. Morris, E. Gros, G. Aldrian-Herrada, M. Choob, J. Archdeacon, F. Heitz, G. Divita, A non-covalent peptide-based carrier for in vivo delivery of DNA mimics, Nucleic Acids Res. 35 (2007) e49.
36. L. Crombez, M.C. Morris, S. Dufort, G. Aldrian-Herrada, Q. Nguyen, G. Mc Master, J.L. Coll, F. Heitz, G. Divita, Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth, Nucleic Acids Res. 37 (2009) 4559-4569.
37. J.C. Reed, The survivin saga goes in vivo, J. Clin. Invest 108 (2001) 965-969. (Pubitemid 32946070)
38. D.C. Altieri, Validating survivin as a cancer therapeutic target, Nat Rev. Cancer 3 (2003) 46-54. (Pubitemid 37328886)
39. V.E. Velculescu, S.L. Madden, L. Zhang, A.E. Lash, J. Yu, C. Rago, A. Lal, C.J. Wang, G.A. Beaudry, K.M. Ciriello, B.P. Cook, M.R. Dufault, AT. Ferguson, Y. Gao, T.C. He, H. Hermeking, S.K. Hiraldo, P.M. Hwang, M.A. Lopez, H.F. Luderer, B. Mathews, J.M. Petroziello, K. Polyak, L. Zawel, W. Zhang, X. Zhang, W. Zhou, F.G. Haluska, J. Jen, S. Sukumar, G.M. Landes, G.J. Riggins, B. Vogelstein, K.W. Kinzler, Analysis of human transcriptomes, Nat Genet 23 (1999) 387-388.
40. B. Busser, L. Sancey, V. Josserand, C. Niang, M.C. Favrot, J.L Coll, A. Hurbin, Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers, Mol. Ther. 18 (2010) 528-535.
41. J.R. Cubillos-Ruiz, X. Engle, U.K. Scarlett, D. Martinez, A. Barber, R Elgueta, L. Wang, Y Nesbeth, Y. Durant, AT. Gewirtz, C.L. Sentman, R. Kedl, J.R. Conejo-Garcia, Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity, J. Clin. Invest. 119 (2009)2231-2244.
42. F. Dif, C. Djediat, O. Alegria, B. Demeneix, G. Levi, Transfection of multiple pulmonary cell types following intravenous injection of PEI-DNA in normal and CFTR mutant mice, J. Gene Med. 8 (2006) 82-89. (Pubitemid 43169384)
43. S.M. Zou, P. Erbacher, J.S. Remy, J.P. Behr, Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse, J. Gene Med. 2 (2000) 128-134.
44. K.A. Price, E.E. Cohen, Current treatment options for metastatic head and neck cancer, Curr. Treat. Options Oncol. 13 (2012) 35-46.
45. M. Song, R. Zhang, Y. Dai, F. Gao, H. Chi, G. Lv, B. Chen, X. Wang, The in vitro inhibition of multidrug resistance by combined nanoparticulate titanium dioxide and UV irradiation, Biomaterials 27 (2006) 4230-4238.
46. I.V. Lebedeva, I. Washington, D. Sarkar, JA Clark, R.L. Fine, P. Dent, DT Curiel, N.J. Turro, P.B. Fisher, Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 3484-3489. (Pubitemid 46364185)
47. F. Greco, M.J. Vicent, Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines, Adv. Drug Deliv. Rev. 61 (2009) 1203-1213.
48. T.M. Sun, J.Z. Du, Y.D. Yao, C.Q. Mao, S. Dou, S.Y. Huang, P.Z. Zhang, K.W. Leong, E.W. Song, J. Wang, Simultaneous delivery of siRNA and paclitaxel via a "two-in-one," micelleplex promotes synergistic tumor suppression, ACS Nano 5 (2011) 1483-1494.
49. M.E. Bonnet, P. Erbacher, A.L. Bolcato-Bellemin, Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response, Pharm. Res. 25 (2008) 2972-2982.
50. O. Gautschi, D.C. Betticher, Molecular therapy in lung cancer, Ther. Umsch. 61 (2004) 365-371.